Jeil Pharmaceutical Co.,Ltd (271980.KS)
KRW 11640.0
(-5.6%)
KRW 11640.0
(-5.6%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 51.97 Billion KRW | 174.94% |
| 2022 | 18.9 Billion KRW | 31.36% |
| 2021 | 14.39 Billion KRW | -68.31% |
| 2020 | 45.41 Billion KRW | 140.16% |
| 2019 | 18.9 Billion KRW | -46.56% |
| 2018 | 35.38 Billion KRW | -22.41% |
| 2017 | 45.6 Billion KRW | 69.67% |
| 2016 | 26.87 Billion KRW | 109.87% |
| 2015 | 12.8 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 53.44 Billion KRW | 2.82% |
| 2024 Q2 | 42.92 Billion KRW | -19.69% |
| 2023 Q1 | 33.06 Billion KRW | 74.9% |
| 2023 FY | 51.97 Billion KRW | 174.94% |
| 2023 Q4 | 51.97 Billion KRW | -6.42% |
| 2023 Q3 | 55.53 Billion KRW | 50.18% |
| 2023 Q2 | 36.98 Billion KRW | 11.86% |
| 2022 FY | 18.9 Billion KRW | 31.36% |
| 2022 Q2 | 25.64 Billion KRW | 139.79% |
| 2022 Q1 | 10.69 Billion KRW | -25.67% |
| 2022 Q4 | 18.9 Billion KRW | -47.01% |
| 2022 Q3 | 35.67 Billion KRW | 39.09% |
| 2021 FY | 14.39 Billion KRW | -68.31% |
| 2021 Q2 | 13.26 Billion KRW | -30.67% |
| 2021 Q1 | 19.13 Billion KRW | -57.86% |
| 2021 Q3 | 4.81 Billion KRW | -63.72% |
| 2021 Q4 | 14.39 Billion KRW | 198.95% |
| 2020 FY | 45.41 Billion KRW | 140.16% |
| 2020 Q1 | 22.24 Billion KRW | 17.67% |
| 2020 Q4 | 45.41 Billion KRW | -4.91% |
| 2020 Q3 | 47.75 Billion KRW | 24.65% |
| 2020 Q2 | 38.31 Billion KRW | 72.21% |
| 2019 Q1 | 20.97 Billion KRW | -40.73% |
| 2019 Q4 | 18.9 Billion KRW | 9.93% |
| 2019 FY | 18.9 Billion KRW | -46.56% |
| 2019 Q3 | 17.2 Billion KRW | 34.07% |
| 2019 Q2 | 12.82 Billion KRW | -38.83% |
| 2018 FY | 35.38 Billion KRW | -22.41% |
| 2018 Q4 | 35.38 Billion KRW | -9.65% |
| 2018 Q3 | 39.16 Billion KRW | 16.17% |
| 2018 Q2 | 33.71 Billion KRW | -12.15% |
| 2018 Q1 | 38.37 Billion KRW | -15.85% |
| 2017 Q3 | 47.77 Billion KRW | 34.84% |
| 2017 Q4 | 45.6 Billion KRW | -4.54% |
| 2017 FY | 45.6 Billion KRW | 69.67% |
| 2017 Q2 | 35.42 Billion KRW | 0.0% |
| 2016 FY | 26.87 Billion KRW | 109.87% |
| 2015 FY | 12.8 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -490.47% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 90.914% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 83.281% |
| HANDOK Inc. | 283.45 Billion KRW | 81.664% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -158.939% |
| Yuhan Corporation | -69.18 Billion KRW | 175.123% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 73.202% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 1510.126% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 89.964% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 260.258% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 31.318% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -41.092% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 37.016% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -107.001% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -490.47% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 132.515% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 74.135% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 69.595% |
| JW Holdings Corporation | 480.68 Billion KRW | 89.187% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 68.42% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -44121.885% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 66.331% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -2110.446% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -125.962% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 70.296% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -490.47% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 67.166% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 85.489% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 66.331% |
| Yuhan Corporation | -69.18 Billion KRW | 175.123% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 61.781% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 12.903% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 87.889% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 66.331% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 55.286% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -216.434% |
| CKD Bio Corp. | 143.29 Billion KRW | 63.729% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 55.22% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 316.006% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 216.186% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -2110.446% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 87.708% |
| Boryung Corporation | 187.72 Billion KRW | 72.314% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 172.348% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 31.318% |
| JW Lifescience Corporation | 26.09 Billion KRW | -99.207% |